Drug updated on 11/15/2023
|Tablet (oral; 200 mg)
|Ongoing and Completed Studies
- For the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Product Monograph / Prescribing Information
|Livtencity (maribavir) Prescribing Information.
|Takeda Pharmaceuticals America Inc., Lexington, MA
Systematic Reviews / Meta-Analyses
|Clinical and pharmacoeconomic combined report.
|Assessment report: Livtencity.
|Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
|Transplantation and Cellular Therapy
Clinical Practice Guidelines
|Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
|The Lancet: Infectious Diseases